Fiche centre
Research Site
Wenzhou — China
Essais liés5clinical trials
VilleWenzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06700616
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Rilvegostomig | Cancer | Phase 3 | NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT05835310 | BLOSSOM — An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | RECRUITING |
| MG Cohort — A Study in Patients With Myasthenia Gravis in China | Myasthénie | À vérifier | NCT06700616 | MG Cohort — A Study in Patients With Myasthenia Gravis in China | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT07751848 | LOTUS — A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus | NOT_YET_RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING |